Une vascularite cryoglobulinémique

In HCV-CryoVas with mild-to-moderate disease, an optimal antiviral treatment should be given, whereas use of immunosuppressants (including corticosteroids) is associated with a poor outcome, and control of disease with rituximab is required before initiation of antiviral therapy.